Piper Jaffray assumed coverage on shares of Infinity Pharmaceuticals (NASDAQ: INFI) in a research note issued to investors on Monday. The firm issued an overweight rating on the stock.
INFI has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase reiterated an overweight rating on shares of Infinity Pharmaceuticals in a research note to investors on Wednesday, March 6th. They now have a $53.00 price target on the stock, up previously from $42.00. Separately, analysts at RBC Capital raised their price target on shares of Infinity Pharmaceuticals from $38.00 to $55.00 in a research note to investors on Wednesday, March 6th. They now have an outperform rating on the stock. Finally, analysts at Stifel Nicolaus raised their price target on shares of Infinity Pharmaceuticals from $39.00 to $50.00 in a research note to investors on Wednesday, March 6th. They now have a buy rating on the stock.
Six analysts have rated the stock with a buy rating, and one has issued a hold rating to the company. Infinity Pharmaceuticals currently has a consensus rating of buy and a consensus target price of $49.00.
Shares of Infinity Pharmaceuticals traded down 0.02% during mid-day trading on Monday, hitting $46.28. Infinity Pharmaceuticals has a 52 week low of $8.63 and a 52 week high of $47.74. The stock’s 50-day moving average is currently $38.60. The company’s market cap is $2.205 billion.
Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company’s lead product candidate is saridegib, also known as IPI-926, an oral molecule that inhibits the Hedgehog pathway by binding to the Smoothened receptor.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
